`2011
`Q1
`2012
`Q2
`Q3
`Q4
`Q1
`2013
`Q2
`Q3
`Q4
`Q1
`2014
`Q2
`Q3
`Q4
`Q1
`2015
`Q2
`Q3
`Q4
`Q1
`2016
`Q2
`Q3
`Q4
`Q1
`2017
`Q2
`Q3
`Q4*
` Q1 2018
`Q2
`Q3
`Q4
`Q1 2019
`Q2
`Q3
`Q4
`Q1
`2020
`Q2
`Q3
`Q4
`Q2 2021
`
`AVASTIN
`
`LUCENTIS
`
`EYLEA
`
`Brolucizumab
`
`63%
`
`57%
`58%
`53%
`48%
`
`48%
`49%
`47%
`51%
`50%
`50%
`48%
`45%
`46%
`43%
`41%
`44%
`
`45%
`44%
`45%
`43%
`
`44%
`44%
`44%
`45%
`44%
`42%
`43%
`42%
`41%
`42%
`40%
`44%
`
`37%
`
`32%
`28%
`27%
`30%
`
`29%
`28%
`27%
`28%
`25%
`29%
`27%
`27%
`22%
`25%
`24%
`21%
`
`18%
`19%
`19%
`20%
`
`19%
`17%
`18%
`18%
`20%
`19%
`20%
`20%
`20%
`20%
`19%
`15%
`
`0%
`
`11%
`14%
`20%
`21%
`
`23%
`23%
`26%
`21%
`24%
`21%
`25%
`28%
`32%
`32%
`35%
`35%
`
`36%
`37%
`36%
`37%
`
`37%
`39%
`38%
`37%
`37%
`39%
`37%
`38%
`39%
`38%
`41%
`39%
`
`42%
`39%
`42%
`40%
`39%
`
`15%
`18%
`14%
`15%
`15%
`
`39%
`39%
`39%
`40%
`42%
`
`2%
`
`4%
`4%
`5%
`5%
`4%
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2226 Page 1
`
`